Skip to main content
Terug
Watch Compare

Upstream Bio, Inc.

Datakwaliteit: 100%
UPB
NASDAQ Manufacturing Chemicals
€ 10,49
▲ € 0,07 (0,67%)
Marktkapitalisatie: 570,87 M
Prijs
€ 10,49
Marktkapitalisatie
570,87 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -133,44 M
Capital efficient — spends only 5,78% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)20,42%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-36,44%
Boven sectorgemiddelde (-54,01%)
ROIC-32,12%
Net Margin-5026,03%
Op. Margin-5618,82%

Veiligheid

Debt / Equity
N/A
Current Ratio32,67
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-3,98 | -3,25
Onder sectorgemiddelde (-1,49)
P/B Ratio1,51
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -4,0 -1,5
P/B 1,5 1,6
ROE % -36,4 -54,0
Net Margin % -5026,0 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

7 analisten
Buy
Huidig
€ 10,49
+315.4%
Koersdoel
€ 43,57
€ 15,00
€ 43,00
€ 75,00
Vooruitzicht
Forward K/W -3,25
Forward WPA -€ 3,23
Omzet Sch. 1,22 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 3,23
-€ 4,02 – -€ 2,07
 1,22 M 6
FY2026 -€ 2,94
-€ 3,67 – -€ 2,33
 1,21 M 8

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,70 -€ 0,78 -11,6%
Q32025 -€ 0,78 -€ 0,63 +19,5%
Q22025 -€ 0,61 -€ 0,74 -21,2%
Q12025 -€ 0,48 -€ 0,51 -5,2%

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
1,06% weight
AVSCX AVSCX
0,08% weight
SHSAX SHSAX
0,08% weight
SHSCX SHSCX
0,08% weight
SHISX SHISX
0,08% weight
VVICX VVICX
0,03% weight
IRCIX IRCIX
0,03% weight
IRSIX IRSIX
0,03% weight
IIRSX IIRSX
0,03% weight
IRSSX IRSSX
0,02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 20,42% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,85 M Net Income (TTM) -143,44 M
ROE -36,44% ROA -35,34%
Gross Margin N/A Operating Margin -5618,82%
Net Margin -5026,03% Free Cash Flow (TTM) -133,44 M
ROIC -32,12% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 32,67
Interest Coverage N/A Asset Turnover 0,01
Working Capital 377,11 M Tangible Book Value 378,58 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,98 Forward P/E -3,25
P/B Ratio 1,51 P/S Ratio 200,02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 469,57 Fwd Earnings Yield N/A
FCF Yield -23,38%
Market Cap 570,87 M Enterprise Value 498,70 M
Per Share
EPS (Diluted TTM) -2,66 Revenue / Share 0,05
FCF / Share -2,45 OCF / Share -2,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 5,78% FCF Conversion 93,03%
SBC-Adj. FCF -145,18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 2,85 M 2,37 M
Net Income -143,44 M -62,81 M
EPS (Diluted) -2,66 -5,58
Gross Profit — —
Operating Income -160,36 M -77,76 M
EBITDA — —
R&D Expenses 136,81 M 62,97 M
SG&A Expenses — —
D&A 188.000,0 89.000,0
Interest Expense — —
Income Tax 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 353,77 M 481,72 M
Total Liabilities 14,00 M 11,87 M
Shareholders' Equity 339,77 M 469,85 M
Total Debt — —
Cash & Equivalents 101,58 M 325,89 M
Current Assets 351,80 M 479,16 M
Current Liabilities 13,45 M 10,74 M